Doravirine, Lamivudine and Tenofovir disoproxil fumarate (delstrigo) Terms of use - Canada.ca * Skip to main content * Skip to "About government" Language selection * FrançaisSearchSearch Canada.ca Search Topics menuMain Menu You are here: 1. Home 2. Health 3. Drug and health products 4. Licensing, authorizing and manufacturing drug and health products 5. Drug and health product review
Lamivudine, dolutegravir sodium (dovato) Skip to main contentSwitch to basic HTML versionLanguage selectionFrançaisSearchSearch Canada.caSearchTopics menuMAINMENU You are here:Home Health Drug and health products Licensing, authorizing and manufacturing drug and health products Drug and health product review and approval Clinical information on drugs and health products Search for clinical
Dolutegravir/abacavir/lamivudine (HIV infection in children) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 6 of the dossier assessment Dolutegravir/Abacavir/Lamivudin (HIV-Infektion bei Kindern) – Nutzenbewertung gemäß § 35a SGB V. Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Dolutegravir/abacavir/lamivudine (HIV infection in children) Benefit assessment according to §35a SGB V1 EXTRACT Project: A23-17 Version: 1.0 Status: 25 May 2023 Extract of dossier assessment A23-17 Version 1.0 Dolutegravir/abacavir/lamivudine ( HIV infection in children) 25 May 2023 Institute for Quality and Efficiency in Health
Doravirine/lamivudine/tenofovir disoproxil (HIV infection) ' Benefit assessment according to '35a Social Code Book V 1 Translation of Sections I 1 to I 5 of the dossier assessment Doravirin/Lamivudin/Tenofovirdisoproxilfumarat (HIV-Infektion bei Jugendlichen) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 July 2022). Please note : This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A22-49 Doravirine/lamivudine/tenofovir disoproxil fumarate (HIV infection in adolescents) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A22-49 Version 1.0 DOR/3TC
Dolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infection A Singapore Government Agency WebsiteHomeHealthcare ProfessionalsACE Technology GuidancesDolutegravir with lamivudine for treating Human Immunodeficiency Virus type 1 (HIV-1) infectionPublished on 19 Dec 2022Last Updated on 19 Dec 2022A-A+Dolutegravir with lamivudine for treating Human Immunodeficiency
dolutegravir / lamivudine (Dovato) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu * Home * COVID-19Specific areasCOVID
doravirine / lamivudine / tenofovir disoproxil fumarate (Delstrigo) Home - All Wales Therapeutics and Toxicology CentreSkip to main contentOpens in new window * NHS Wales * NHS 111 Wales * Skip Navigation * Accessibility * Contact us * CymraegCymraeg * Welcome to All Wales Therapeutics and Toxicology Centre * All...SearchAll Wales Therapeutics and Toxicology CentreSearchCymraegCymraegMenu
Dolutegravir/lamivudine (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dolutegravir/Lamivudin (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 30 October 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-55 Dolutegravir/lamivudine (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A19-55 Version 1.0 Dolutegravir/lamivudine ( HIV infection) 30 October 2019 Institute for Quality
Dolutegravir/lamivudine (HIV infection) - Second Addendum to Commission A19-55 1 Translation of addendum A19-103 (Dolutegravir/Lamivudin) – Addendum zum Auftrag A19-55 (Version 1.0; Status: 22 January 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 22 January 2020 1.0 Commission: A19-103 Version: Status: IQWiG Reports – Commission No. A19-103 Dolutegravir/lamivudine (HIV infection 1) – 2nd addendum to Commission A19-551 Addendum A10-103 Version 1.0 Dolutegravir/lamivudine (HIV infection 1) – Addendum to Commission A19-55 22 January 2020 Institute for Quality and Efficiency in Health Care (IQWiG
Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons with Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicentre, Phase IIA Clinical Trial. We investigated the efficacy of dolutegravir/lamivudine for maintenance treatment for people with HIV and previous lamivudine resistance. Open-label, single arm , multicentric clinical trial including virologically suppressed PWH with historical lamivudine resistance (confirmed by genotypic testing or suspected based on clinical history), no integrase resistance and CD4+ >200 cells/mm3 whose ART was changed to dolutegravir/lamivudine if the M184V/I mutation was not detected in baseline proviral DNA population sequencing. Proviral DNA next-generation sequencing (NGS
Doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo) - HIV Published 8 March 2021 1 Product update SMC2333 doravirine/lamivudine/tenofovir disoproxil fumarate 100mg/300mg/245mg film-coated tablets (Delstrigo®) Merck Sharp & Dohme (UK) Limited 5 February 2021 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following an abbreviated submission doravirine/lamivudine/tenofovir disoproxil fumarate (Delstrigo®) is accepted for use within NHSScotland. Indication under review: for the treatment of adults infected with HIV-1 without past or present
Doravirine/lamivudine/tenofovir disoproxil (HIV infection) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Doravirin/Lamivudin/Tenofovirdisoproxilfumarat (HIV-Infektion) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 11 April 2019). Please note : This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A19-05 Doravirine/lamivudine/tenofovir disoproxil fumarate (HIV infection) – Benefit assessment according to §35a Social Code Book V1 Extract of dossier assessment A19-05 Version 1.0 Doravirine/lamivudine/tenofovir
Assessment of risk factors for virological nonsuppression following switch to dolutegravir and lamivudine, or bictegravir, emtricitabine, and tenofovir alafenamide fumarate in a real-world cohort of treatment-experienced adults living with HIV. Conflicting data exists regarding the baseline determinants of virological nonsuppression outcomes in treatment-experienced people living with human immunodeficiency virus (PWH) switching to antiretroviral treatment (ART) with bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) or dolutegravir/lamivudine (DTG/3TC) in Asia. This retrospective observational study, conducted at a designated HIV-care hospital from October 2019 to January 2023, aimed to address this gap. We assessed the odds of virological nonsuppression (VNS) at weeks 48 using
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, ope With longer life expectancy in people living with HIV (PLWH) on antiretroviral therapy, cardiovascular disease (CVD) has become a common cause of virologically suppressed PLWH on dolutegravir, abacavir and lamivudine (DTG/ABC/3TC) for ≥6 months. In total, 70 PLWH will be randomised 1:2 to either continue DTG/ABC/3TC or to switch to dolutegravir and lamivudine (DTG/3TC) providing the power of 80% at alpha 5% to detect a mean difference in weight change of 2 kg (Δ) given an SD of 2.7 kg. Follow-up will be 48 weeks. Data will be collected at baseline
Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study. Lamivudine plus dolutegravir (3TC/DTG) and bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) regimens are commonly used as first-line treatments for people living with human
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial. Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without baseline resistance testing raises concerns about the potential presence of pretreatment lamivudine resistance. We aimed to evaluate the efficacy of dolutegravir plus lamivudine in the absence of information on baseline resistance testing in treatment-naive people with HIV. We did an open-label, non-inferiority, single-centre, phase 4, randomised controlled study (D2ARLING), designed to assess the efficacy and safety of dolutegravir plus lamivudine
Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms. We investigated the steady-state pharmacokinetics of generic abacavir (ABC)/lamivudine (3TC) dispersible tablets (DTs) in young children living with HIV aged 3 months to <7 years, weighing 6 to <20 kg. Twenty-eight Thai children were enrolled
'With age comes wisdom': effectiveness and tolerability of dolutegravir + lamivudine in virologically-suppressed people with HIV. Results from clinical trials and observational studies suggest that dolutegravir plus lamivudine is a well tolerated option for simplification in people with HIV (PWH). We aimed to assess long-time effectiveness and safety in our cohort. We performed an observational study enrolling HIV-1-infected, virologically suppressed PWH, switching to dolutegravir plus lamivudine. Exclusion criteria were HBV-coinfection and the presence of the M184V mutation before the simplification. We performed survival analysis to evaluate time to virological failure (VF, defined by a single HIV-RNA ≥200 copies/ml or by two consecutive HIV-RNA ≥ 50 copies/ml) and treatment